Ocular Genomics
243 Charles Street Boston, MA 02114 Contact us
Diagnostic Testing
Support our research
Explore our labs
Ocular Genomics MENU
Ocular Genomics
  • Meet the Team
  • Services
    • Biobank Core Services
    • Bioinformatics and Statistics Core
    • Functional Genomics (Zebrafish) Core
    • Gene Transfer Vector
      • Rates
      • Order Information
      • Contact Us
    • Genetic Diagnostic Testing Service
      • Pricing
    • Genomics Core Services
      • Additional Genomics Services
      • Sanger Sequencing
      • Array Analysis
      • Next-Generation Sequencing (NGS)
  • Labs
    • Biobank Core
    • Bujakowska Lab
      • Lab Members
      • Publications
    • Comander Lab
      • Lab Members
      • Publications
    • Engle Lab
      • Lab Members
    • Fernandez-Godino Lab
      • Lab Members
      • Macular Degeneration
      • Publications
    • Functional Genomics Core (Zebrafish Facility)
      • Lab Members
    • Genetic Counseling Team
      • Team Members
    • Genomics Core Lab
      • Lab Members
    • Liu Lab
      • Lab Members
      • Publications
      • Projects
    • MEEI Bioinformatics Center (MBC)
      • Lab Members
    • Pierce Lab
      • Lab Members
      • Publications
      • Projects
    • Segrè Lab
      • Selected Publications
    • Vandenberghe Lab
      • Lab Members
    • Wiggs Lab
      • Lab Members
  • News & Publications
    • RETINAL Transcriptome
  • Affiliates
  • Careers
  • Home
  • News
  • 2018 Genentech AMD Translational Research Fellowship recipient: Chari Fernandez-Godino, PhD

Featured Posts

  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder

Recent Posts

  • Precision Medicine at Work
  • Work by Caitlin Collin & Qin Liu highlighted at ARVO 2021 meeting
  • Ground-breaking study to restore vision uses CRISPR technology
  • Ocular Genomics Institute Scientists publish large Gene-Wide Association Study of Glaucoma
  • AAVCOVID Vaccine developed by Luk Vandenberghe to start Clinical trials

Archives

  • June 2021
  • May 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • August 2019
  • May 2019
  • April 2019
  • May 2018
  • April 2018
  • March 2018
  • November 2017
  • September 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017

Categories

  • News
  • Publication
  • Uncategorized

2018 Genentech AMD Translational Research Fellowship recipient: Chari Fernandez-Godino, PhD
April 29, 2019

Chari Fernandez-Godino has been awarded a fellowship from the ARVO foundation to support her research on AMD. The award ceremony took place at ARVO 2019.

Project title
Targeting complement activation via tick-over: a prophylactic treatment for dry AMD

About Dr. Fernandez-Godino’s project
As many as 11 million people in the US has some form of macular degeneration; this number is expected to double to 22 million in the next 30 years. Current therapies can improve vision only in some patients with advanced age-related macular degeneration (AMD); unfortunately, there is no effective therapy that prevents disease progression in patients with early/intermediate disease. The first clinical sign of AMD is the formation of drusen, which appear as yellow spots in the fundus of the eye and which mechanism of formation is unclear. We need to understand how drusen forms, and how aging and genes participate in this process in order to develop drugs that stop AMD progression. The most important genes associated with AMD belong to the complement system, which is an important part of the immune system that attacks bacteria. Mutations in these genes along with age may cause that the complement attacks your own retinal cells inappropriately, which results in drusen formation. We have developed a model that mimics the formation of drusen in a dish. We will use this model to test if the blockage of two essential components of the complement system, C3 and CFB, can be used as a prophylactic therapy to prevent the progression of drusen to blindness.

Featured:

Contact Us

243 Charles Street
Boston, MA 02114

Labs

  • Engle Lab
  • Pierce Lab
  • Vandenberghe Lab
  • Wiggs Lab
  • Genomics Core Lab
  • Functional Genomics Core (Zebrafish Facility)
  • MEEI Bioinformatics Center (MBC)

Sitemap

  • Affiliates
  • Careers
  • Meet the Team
  • News & publications
  • Support Our Research
  • Services
  • Privacy
website-boston WebsiteBoston